Literature DB >> 12756137

Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment.

Angela L Guillozet1, Sandra Weintraub, Deborah C Mash, M Marsel Mesulam.   

Abstract

BACKGROUND: Large numbers of neurofibrillary tangles (NFTs) and amyloid plaques are diagnostic markers for Alzheimer disease (AD), but lesser numbers of these lesions are also seen in nondemented elderly individuals. Much of the existing literature suggests that the NFTs of AD have a closer correlation with cognitive function than do amyloid plaques. Whether a similar relationship exists in normal aging and mild cognitive impairment (MCI), a condition that frequently reflects a preclinical stage of AD, remains unknown.
OBJECTIVE: To determine the distribution patterns of beta-amyloid plaques and NFTs and the association of these lesions with memory performance in nondemented individuals.
METHODS: We investigated regional distributions and neuropsychological correlates of NFTs and amyloid plaques in cognitively normal elderly persons and subjects with MCI who received neuropsychological testing before death. Subjects Eight nondemented subjects who volunteered to receive annual neuropsychological testing and agreed to brain donation were studied. Five subjects showed no cognitive impairment, and 3 were diagnosed with MCI.
RESULTS: Distribution of NFTs followed a rigorous and hierarchical pattern, but distribution of amyloid plaques varied among individuals. Subjects with MCI displayed higher NFT densities than did nonimpaired subjects. In addition, NFT density in the temporal lobe correlated with memory scores, whereas density of amyloid plaques did not.
CONCLUSIONS: Neurofibrillary tangles are more numerous in medial temporal lobe regions associated with memory function and show a relationship to performance on memory tests in nondemented individuals. These results suggest that NFTs may constitute a pathological substrate for memory loss not only in AD but also in normal aging and MCI.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12756137     DOI: 10.1001/archneur.60.5.729

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  204 in total

Review 1.  Mild cognitive impairment: pathology and mechanisms.

Authors:  Elliott J Mufson; Lester Binder; Scott E Counts; Steven T DeKosky; Leyla de Toledo-Morrell; Stephen D Ginsberg; Milos D Ikonomovic; Sylvia E Perez; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-11-19       Impact factor: 17.088

2.  Neurodegenerative basis of age-related cognitive decline.

Authors:  R S Wilson; S E Leurgans; P A Boyle; J A Schneider; D A Bennett
Journal:  Neurology       Date:  2010-09-15       Impact factor: 9.910

3.  Predicting cognitive decline and conversion to Alzheimer's disease in older adults using the NAB List Learning test.

Authors:  Brandon E Gavett; Al Ozonoff; Vlada Doktor; Joseph Palmisano; Anil K Nair; Robert C Green; Angela L Jefferson; Robert A Stern
Journal:  J Int Neuropsychol Soc       Date:  2010-04-07       Impact factor: 2.892

4.  Sensitive quantitative assays for tau and phospho-tau in transgenic mouse models.

Authors:  Christopher M Acker; Stefanie K Forest; Ray Zinkowski; Peter Davies; Cristina d'Abramo
Journal:  Neurobiol Aging       Date:  2012-06-21       Impact factor: 4.673

5.  Characterization of the radiolabeled metabolite of tau PET tracer 18F-THK5351.

Authors:  Ryuichi Harada; Shozo Furumoto; Tetsuro Tago; Katsutoshi Furukawa; Aiko Ishiki; Naoki Tomita; Ren Iwata; Manabu Tashiro; Hiroyuki Arai; Kazuhiko Yanai; Yukitsuka Kudo; Nobuyuki Okamura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-07-19       Impact factor: 9.236

6.  Polysomnographic and subjective sleep markers of mild cognitive impairment.

Authors:  Eva Hita-Yañez; Mercedes Atienza; Jose L Cantero
Journal:  Sleep       Date:  2013-09-01       Impact factor: 5.849

7.  Braak staging, plaque pathology, and APOE status in elderly persons without cognitive impairment.

Authors:  Elliott J Mufson; Michael Malek-Ahmadi; Sylvia E Perez; Kewei Chen
Journal:  Neurobiol Aging       Date:  2015-10-20       Impact factor: 4.673

Review 8.  Hyperphosphorylated tau is implicated in acquired epilepsy and neuropsychiatric comorbidities.

Authors:  Ping Zheng; Sandy R Shultz; Chris M Hovens; Dennis Velakoulis; Nigel C Jones; Terence J O'Brien
Journal:  Mol Neurobiol       Date:  2013-12-10       Impact factor: 5.590

Review 9.  Mild cognitive impairment: ten years later.

Authors:  Ronald C Petersen; Rosebud O Roberts; David S Knopman; Bradley F Boeve; Yonas E Geda; Robert J Ivnik; Glenn E Smith; Clifford R Jack
Journal:  Arch Neurol       Date:  2009-12

10.  Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease.

Authors:  W J P Henneman; H Vrenken; J Barnes; I C Sluimer; N A Verwey; M A Blankenstein; M Klein; N C Fox; P Scheltens; F Barkhof; W M van der Flier
Journal:  Neurology       Date:  2009-09-22       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.